A countermeasure for microthrombosis and tissue injury in freezing cold injury that prevents pathologic fibrinogen elevation
Active Project Grant Awarded Last action
- Award ID
- HT9425261E103
- Recipient
-
Versiti Blood Health, Inc. UEI JZDRNT166LE4
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,699,998
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 11% complete
- Place of performance
- Milwaukee, WI 53233, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded $1.7 million to Versiti Blood Health, Inc. on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop a countermeasure for microthrombosis and tissue injury in freezing cold injury that prevents pathologic fibrinogen elevation. The award runs through June 30, 2029, with performance at Versiti's Milwaukee, Wisconsin location. The project grant is one of six Defense Health Agency awards to Versiti, which operates the Blood Research Institute as its translational and basic science center and maintains an established federal research portfolio anchored by National Heart, Lung, and Blood Institute funding.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Hennepin Healthcare Research Institute | $58,622 |
Quick answers
Who received award HT9425261E103?
HT9425261E103 was awarded to Versiti Blood Health, Inc. by Defense Health Agency (Department of Defense) on July 1, 2026.
How much is award HT9425261E103 worth?
$1,699,998 has been obligated on HT9425261E103.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award